Form 8-K - Current report:
SEC Accession No. 0002023658-25-000063
Filing Date
2025-06-06
Accepted
2025-06-06 16:47:19
Documents
12
Period of Report
2025-06-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bcax-20250602.htm   iXBRL 8-K 26113
  Complete submission text file 0002023658-25-000063.txt   148467

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20250602.xsd EX-101.SCH 1779
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20250602_lab.xml EX-101.LAB 23435
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20250602_pre.xml EX-101.PRE 13579
14 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20250602_htm.xml XML 2910
Mailing Address 245 MAIN STREET CAMBRIDGE MA 02142
Business Address 245 MAIN STREET CAMBRIDGE MA 02142 617-785-8308
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42271 | Film No.: 251031402
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)